The 3D Medicine Printing Conference will take place on February 01, 2017, at MECC Maastricht in The Netherlands.
The conference will focus on the following areas:
- Research & Development in 3D Medicine / Drug Printing
- New materials (Active Pharmaceutical Ingredients)
- Changing value chains in the Pharmaceutical industry
- 3D Dental/Oral Scanning
- 3D Software tools
- Pharmacy of the future
- The Changing role of the Doctor
- Ethical /legal issues
- Printing your own drugs (DIY)
The conference is part of the 3D Medical Expo, an event that includes a two-day exhibition and three other conferences besides the 3D Medicine Printing:
Find more about the 2016 edition!
Who should attend?
Pharmaceutical, biopharmaceutical and Biotech professionals, Regulators, Research Institutes, Compliance Officers, Pharmacists, Doctors, Laboratory Personnel, Consultants, Contractors/Subcontractors, 3D Printing suppliers, anyone responsible for medicine/drug: Development | Manufacturing | Preclinical | Quality Assurance | Quality Control | Operations.
Fast Facts about 3D Medicine Printing
The role of medicines in healthcare systems globally is becoming more important. Innovative treatments become available to address unmet clinical needs at the same time that economic development and the imperative of universal health coverage become drivers of expanded access.
In 2014 it is estimated that the global spending on medicines exceeded $1 trillion for the first time. The amount is projected to reach $1.2 trillion in 2017.
The traditional value chain of medicines involves three major components:
- Manufacturing of the medicine
- Distribution to the dispensing point
- Dispensing to the end user (Providing the correct medicine dosage and form)
Now 3D Printing comes in. It will have a strong impact on the value chain as the industry can start with low-volume production and personalised medicine, but also produce a wide range of APIs (Active Pharmaceutical Ingredients) on demand for use in medicine R&D.
Going a step further, on-demand drug-printing facilities at clinics and pharmacies, or even in patients’ homes, could allow doctors to improve treatment by creating tailored dosing regimens. In addition to this, doses could be personalised with individual colours, flavours and shapes to appeal to individual patient which will boost their adherence.
As 3D printing capabilities develop further, safety and regulatory concerns are addressed and the cost of the technology falls, contract manufacturers and pharmaceutical companies that experiment with these 3D printing innovations are likely to gain a competitive edge.